1
|
Bravo-Osuna I, Vicario-de-la-Torre M, Andrés-Guerrero V, Sánchez-Nieves J, Guzmán-Navarro M, de la Mata FJ, Gómez R, de Las Heras B, Argüeso P, Ponchel G, Herrero-Vanrell R, Molina-Martínez IT. Novel Water-Soluble Mucoadhesive Carbosilane Dendrimers for Ocular Administration. Mol Pharm 2016; 13:2966-76. [PMID: 27149661 DOI: 10.1021/acs.molpharmaceut.6b00182] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The purpose of this research was to determine the potential use of water-soluble anionic and cationic carbosilane dendrimers (generations 1-3) as mucoadhesive polymers in eyedrop formulations. Cationic carbosilane dendrimers decorated with ammonium -NH3(+) groups were prepared by hydrosylilation of Boc-protected allylamine and followed by deprotection with HCl. Anionic carbosilane dendrimers with terminal carboxylate groups were also employed in this study. In vitro and in vivo tolerance studies were performed in human ocular epithelial cell lines and rabbit eyes respectively. The interaction of dendrimers with transmembrane ocular mucins was evaluated with a surface biosensor. As proof of concept, the hypotensive effect of a carbosilane dendrimer eyedrop formulation containing acetazolamide (ACZ), a poorly water-soluble drug with limited ocular penetration, was tested after instillation in normotensive rabbits. The methodology used to synthesize cationic dendrimers avoids the difficulty of obtaining neutral -NH2 dendrimers that require harsher reaction conditions and also present high aggregation tendency. Tolerance studies demonstrated that both prototypes of water-soluble anionic and cationic carbosilane dendrimers were well tolerated in a range of concentrations between 5 and 10 μM. Permanent interactions between cationic carbosilane dendrimers and ocular mucins were observed using biosensor assays, predominantly for the generation-three (G3) dendrimer. An eyedrop formulation containing G3 cationic carbosilane dendrimers (5 μM) and ACZ (0.07%) (289.4 mOsm; 5.6 pH; 41.7 mN/m) induced a rapid (onset time 1 h) and extended (up to 7 h) hypotensive effect, and led to a significant increment in the efficacy determined by AUC0(8h) and maximal intraocular pressure reduction. This work takes advantage of the high-affinity interaction between cationic carbosilane dendrimers and ocular transmembrane mucins, as well as the tensioactive behavior observed for these polymers. Our results indicate that low amounts of cationic carbosilane dendrimers are well tolerated and able to improve the hypotensive effect of an acetazolamide solution. Our results suggest that carbosilane dendrimers can be used in a safe range of concentrations to enhance the bioavailability of drugs topically administered in the eye.
Collapse
Affiliation(s)
- I Bravo-Osuna
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain.,Pharmaceutical Innovation in Ophthalmology Research Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III , Calle Profesor Martín Lagos, s/n, 28040 Madrid, Spain.,Instituto Universitario de Farmacia Industrial (IUFI), School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain
| | - M Vicario-de-la-Torre
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain.,Pharmaceutical Innovation in Ophthalmology Research Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III , Calle Profesor Martín Lagos, s/n, 28040 Madrid, Spain.,Instituto Universitario de Farmacia Industrial (IUFI), School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain
| | - V Andrés-Guerrero
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain.,Pharmaceutical Innovation in Ophthalmology Research Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III , Calle Profesor Martín Lagos, s/n, 28040 Madrid, Spain.,Instituto Universitario de Farmacia Industrial (IUFI), School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain
| | - J Sánchez-Nieves
- Department of Organic and Inorganic Chemistry, University of Alcalá , Plaza San Diego, 28801 Alcalá de Henares, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Plaza San Diego, 28801 Alcalá de Henares, Spain
| | - M Guzmán-Navarro
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Alcalá de Henares , Plaza San Diego, 28801 Alcalá de Henares, Spain
| | - F J de la Mata
- Department of Organic and Inorganic Chemistry, University of Alcalá , Plaza San Diego, 28801 Alcalá de Henares, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Plaza San Diego, 28801 Alcalá de Henares, Spain
| | - R Gómez
- Department of Organic and Inorganic Chemistry, University of Alcalá , Plaza San Diego, 28801 Alcalá de Henares, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Plaza San Diego, 28801 Alcalá de Henares, Spain
| | - B de Las Heras
- Department of Pharmacology, School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain
| | - P Argüeso
- Schepens Eye Research Institute and Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School , Boston, Massachusetts 02114, United States
| | - G Ponchel
- CNRS UMR 8612, Université de Paris Sud, Laboratoire de Physicochimie, Pharmacotechnie et Biopharmacie, Faculté de Pharmacie, Université Paris-Sud 5 , rue Jean-Baptiste Clément, 92 296 Châtenay-Malabry, Paris, France
| | - R Herrero-Vanrell
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain.,Pharmaceutical Innovation in Ophthalmology Research Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III , Calle Profesor Martín Lagos, s/n, 28040 Madrid, Spain.,Instituto Universitario de Farmacia Industrial (IUFI), School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain
| | - I T Molina-Martínez
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain.,Pharmaceutical Innovation in Ophthalmology Research Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III , Calle Profesor Martín Lagos, s/n, 28040 Madrid, Spain.,Instituto Universitario de Farmacia Industrial (IUFI), School of Pharmacy, University Complutense , Avenida Complutense, 28040 Madrid, Spain
| |
Collapse
|
2
|
Heredero-Bermejo I, Sánchez-Nieves J, Soliveri J, Gómez R, de la Mata FJ, Copa-Patiño JL, Pérez-Serrano J. In vitro anti-Acanthamoeba synergistic effect of chlorhexidine and cationic carbosilane dendrimers against both trophozoite and cyst forms. Int J Pharm 2016; 509:1-7. [PMID: 27173821 DOI: 10.1016/j.ijpharm.2016.04.075] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 04/27/2016] [Accepted: 04/28/2016] [Indexed: 11/28/2022]
Abstract
Acanthamoeba sp. are the causative agents of severe illnesses in humans such as Acanthamoeba keratitis (AK) and granulomatous amoebic encephalitis (GAE). Medical therapy is not yet well established. Treatments of AK last for several months and generate toxicity, resistances appear due to the cysts stage and recurrences can occur. In this study has been demonstrated that the combination of chlorhexidine digluconate (CLX) and carbosilane dendrimers containing ammonium or guanidine moieties has in vitro synergistic effect against Acanthamoeba polyphaga. This synergy provokes an important reduction in the minimal trophozoite amoebicidal concentration (MTAC) of CLX, which means a reduction of their toxic effects on human cells. Moreover, some CLX/dendrimer combinations show important activity against the cyst resistance stage.
Collapse
Affiliation(s)
- I Heredero-Bermejo
- Departamento de Biomedicina y Biotecnología, Facultad de Farmacia, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain.
| | - J Sánchez-Nieves
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Farmacia, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain; Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - J Soliveri
- Departamento de Biomedicina y Biotecnología, Facultad de Farmacia, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| | - R Gómez
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Farmacia, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain; Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - F J de la Mata
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Farmacia, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain; Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - J L Copa-Patiño
- Departamento de Biomedicina y Biotecnología, Facultad de Farmacia, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| | - J Pérez-Serrano
- Departamento de Biomedicina y Biotecnología, Facultad de Farmacia, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| |
Collapse
|